AI-driven drug innovation research: Trends, challenges, and countermeasures

Authors

• Tian MIAO, School of Economics and Management, University of Chinese Academy of Sciences, Beijing 100190, ChinaFollow
• Qi ZHOU, School of Business Administration, South China University of Technology, Guangzhou 510641, ChinaFollow
• Lianzheng ZHOU, School of Business Administration, South China University of Technology, Guangzhou 510641, China
• Weijun XU, School of Business Administration, South China University of Technology, Guangzhou 510641, China
• Siyuan LIU, School of Business Administration, South China University of Technology, Guangzhou 510641, China

Keywords

artificial intelligence, drug research and development, scientific and technological innovation

Abstract

Artificial intelligence (AI) is profoundly transforming the innovation paradigm, industrial ecosystem, and business model of drug research and development. In recent years, the global AI-driven pharmaceutical market has grown rapidly. Major economies, multinational pharmaceutical enterprises, and technology giants are accelerating their strategic deployment. AI pharmaceutical industry has entered a critical stage of transitioning from proof-of-concept to commercial-application. China attaches great importance to the integrated development of AI and the biopharmaceutical industry, but it still faces challenges, including data scarcity, talent shortages, algorithmic black-boxes, regulatory lag, and weak foundations. This study proposes measures from the aspects of data supply, talent cultivation, technology verification, governance reform, and ecosystem building, aiming to provide strategic references for promoting the high-quality development of China’s AI pharmaceutical industry.

First page

2186

Last Page

2195

Language

Chinese

Publisher

Bulletin of Chinese Academy of Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.

References

[1] Zhang K, Yang X, Wang Y, et al. Artificial intelligence in drug development. Nature Medicine, 2025, 31(1): 45-59.

[2] Dharmasivam M, Azad M G, Richardson V, et al. Artificial intelligence-assisted drug discovery in 2025: Faster, but is it better? The robots are coming, look out!. Pharmacological Reviews, 2026, 78(1): 100103.

[3] 李鑫, 于汉超. 人工智能驱动的生命科学研究新范式. 中国科学院院刊, 2024, 39(1): 51-58. Li X, Yu H C. A new paradigm of life science research driven by artificial intelligence. Bulletin of Chinese Academy of Sciences, 2024, 39(1): 51-58. (in Chinese)

[4] 何欣恒, 高斯涵, 李俊睿, 等. 人工智能驱动药物研发进展. 科技导报, 2025, 43(12): 29-37. He X H, Gao S H, Li J R, et al. Progress of artificial intelligence-driven drug discovery. Science & Technology Review, 2025, 43(12): 29-37. (in Chinese)

[5] Lou B, Wu L. AI on drugs: Can artificial intelligence accelerate drug development? Evidence from a large-scale examination of bio-pharma firms. MIS Quarterly, 2021, 45(3): 1451-1482.

[6] Dharmasivam M, Kaya B, Akinware A, et al. Leading artificial intelligence-driven drug discovery platforms: 2025 landscape and global outlook. Pharmacological Reviews, 2026, 78(1): 100102.

[7] 陈凯先, 刘丽丽, 黄瑶庆, 等. 生物医药创新与人工智能融合发展的现状与展望. 中国药学杂志, 2026, 61(1): 1-6. Chen K X, Liu L L, Huang Y Q, et al. Current status and future prospects of the integrated development of biomedical innovation and artificial intelligence. Chinese Pharmaceutical Journal, 2026, 61(1): 1-6. (in Chinese)

[8] 刘云, 房浩超. 人工智能赋能产业创新生态系统动态演进：驱动因素与具体路径. 科技进步与对策, 2025, 42(13): 1-13. Liu Y, Fang H C. The dynamic evolution of artificial intelligence-empowered industrial innovation ecosystem: Driving factors and specific paths. Science & Technology Progress and Policy, 2025, 42(13): 1-13. (in Chinese)

[9] 张琦, 刘中全. 人工智能在生物医药领域的应用前景分析及对策建议. 中国生物工程杂志, 2025, 45(10): 135-142. Zhang Q, Liu Z Q. Analysis of the application prospects and strategic measures for artificial intelligence in the field of biomedicine. China Biotechnology, 2025, 45(10): 135-142. (in Chinese)

[10] 江海平, 高纯纯, 刘文豪, 等. 数据驱动的生命科学研究进展. 中国科学院院刊, 2024, 39(5): 862-871. Jiang H P, Gao C C, Liu W H, et al. Advances in data-driven life sciences research. Bulletin of Chinese Academy of Sciences, 2024, 39(5): 862-871. (in Chinese)

[11] Freilich J, Rai A K. What patents on AI-derived drugs reveal. Science, 2025, 388(6750): 924-926.

[12] 郑晓莹, 刘春蕾, 刘乔蔚. 造福于民，还是唯利是图？消费者对AI制药的感知与反应. 南开管理评论, 2025, 28(3): 4-15. Zheng X Y, Liu C L, Liu Q W. Benefiting the public or pursuing profit? Consumer perception and response to AI drug. Nankai Business Review, 2025, 28(3): 4-15. (in Chinese)

[13] Freilich J, Rai A K. Patents on AI-derived drugs: Empirical evidence and legal challenges. Nature Biotechnology, 2026, 44(3): 362-364.

[14] Panagopoulos A, Sideri K, Cohen I G, et al. Innovation and policy challenges of AI-drug hybrids. Nature Biotechnology, 2026, 44(3): 365-368.

[15] 王楠, 王国强. 新竞争格局下中美生物医药创新对比研究. 中国软科学, 2023, (1): 22-31. Wang N, Wang G Q. Comparative analysis on the biopharmaceutical innovation of China and United States in a new era of China-US competition. China Soft Science, 2023, (1): 22-31. (in Chinese)

[16] 徐萍, 许丽, 杨若南, 等. 新药研发发展态势分析. 中国科学院院刊, 2024, 39(5): 821-831. Xu P, Xu L, Yang R N, et al. Analysis of research and development trends of new drugs. Bulletin of Chinese Academy of Sciences, 2024, 39(5): 821-831. (in Chinese)

[17] Krieger J, Li D, Papanikolaou D. Missing novelty in drug development. The Review of Financial Studies, 2022, 35(2): 636-679.

[18] 中国科学院创新范式研究组. 加快人工智能驱动的知识创新体系建设. 中国科学院院刊, 2025, 40(10): 1709-1719. Innovation Paradigm Research Group, Chinese Academy of Sciences. Accelerating the development of AI-driven knowledge innovation system. Bulletin of Chinese Academy of Sciences, 2025, 40(10): 1709-1719. (in Chinese)

Recommended Citation

MIAO, Tian; ZHOU, Qi; ZHOU, Lianzheng; XU, Weijun; and LIU, Siyuan (2026) "AI-driven drug innovation research: Trends, challenges, and countermeasures," Bulletin of Chinese Academy of Sciences (Chinese Version): Vol. 41 : Iss. 10 , Article 16.
DOI: https://doi.org/10.3724/j.issn.1000-3045.20260430004
Available at: https://bulletinofcas.researchcommons.org/journal/vol41/iss10/16